Drug Type Small molecule drug |
Synonyms Irsenontrine, Irsenontrine maleate, E 2027 + [5] |
Target |
Mechanism PDE9A inhibitors(Phosphodiesterase 9A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H26N4O7 |
InChIKeyAFKSGMDXSLTKSU-DASCVMRKSA-N |
CAS Registry1630083-70-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lewy Body Disease | Phase 3 | IT | 19 Apr 2018 | |
Parkinson Disease | Phase 3 | - | - | |
Dementia due to Parkinson's disease | Phase 2 | US | 25 Feb 2021 | |
Dementia due to Parkinson's disease | Phase 2 | CA | 25 Feb 2021 |
Phase 2 | 34 | (DLB Without Amyloid Copathology) | akmsqhsgpr(lgjjyteimy) = rodobludcm rdmmbfkmsp (hhgsvnvgmu, bueijdmwvr - oxmsyyykpk) View more | - | 26 Sep 2022 | ||
(DLB With Amyloid Copathology) | akmsqhsgpr(lgjjyteimy) = gdcvsqemui rdmmbfkmsp (hhgsvnvgmu, ccndstzqmb - mtusejwmzu) View more | ||||||
Not Applicable | - | hezjsvezsr(fkeoskqqys) = kqnlkjirpn nnjnkjcigu (rkwogqjpcg ) | - | 01 Jul 2018 |